{"transactions":[{"id":2655,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":1941,"kind":"person","name":"JONES WILLIAM A JR","position":1,"cik":"0001373097","reported_name":"JONES WILLIAM A JR","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2026-09-03T20:39:16.000Z","date":"2026-09-03","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":7657,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Each reported option was disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the per share merger consideration of $135.11 over the exercise price of such option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The reported options were vested as of the date of the Merger or became fully vested in connection with the Merger."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Each reported option was disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the per share merger consideration of $135.11 over the exercise price of such option."}],"balance_after":0,"derivative":{"exercise_price":85,"expiration_date":"2036-06-09","underlying":"Common Stock","underlying_shares":7657},"source":{"system":"sec-edgar","filing":"0001140361-26-035614","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1974640/000114036126035614/form4.xml","form_type":"4"}},{"id":2654,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":1941,"kind":"person","name":"JONES WILLIAM A JR","position":1,"cik":"0001373097","reported_name":"JONES WILLIAM A JR","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2026-09-03T20:39:16.000Z","date":"2026-09-03","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":14461,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Each reported option was disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the per share merger consideration of $135.11 over the exercise price of such option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The reported options were vested as of the date of the Merger or became fully vested in connection with the Merger."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Each reported option was disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the per share merger consideration of $135.11 over the exercise price of such option."}],"balance_after":0,"derivative":{"exercise_price":41.66,"expiration_date":"2035-06-17","underlying":"Common Stock","underlying_shares":14461},"source":{"system":"sec-edgar","filing":"0001140361-26-035614","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1974640/000114036126035614/form4.xml","form_type":"4"}},{"id":2653,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":1941,"kind":"person","name":"JONES WILLIAM A JR","position":1,"cik":"0001373097","reported_name":"JONES WILLIAM A JR","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2026-09-03T20:39:16.000Z","date":"2026-09-03","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":10370,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Each reported option was disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the per share merger consideration of $135.11 over the exercise price of such option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The reported options were vested as of the date of the Merger or became fully vested in connection with the Merger."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Each reported option was disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the per share merger consideration of $135.11 over the exercise price of such option."}],"balance_after":0,"derivative":{"exercise_price":43.85,"expiration_date":"2034-06-05","underlying":"Common Stock","underlying_shares":10370},"source":{"system":"sec-edgar","filing":"0001140361-26-035614","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1974640/000114036126035614/form4.xml","form_type":"4"}},{"id":2652,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":1941,"kind":"person","name":"JONES WILLIAM A JR","position":1,"cik":"0001373097","reported_name":"JONES WILLIAM A JR","relationship":{"director":true}}],"security":"Common Stock","published_at":"2026-09-03T20:39:16.000Z","date":"2026-09-03","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":34824,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The reported securities represent shares of the Issuer's common stock disposed of pursuant to the terms of the Agreement and Plan of Merger, dated as of June 18, 2026 (the \"Merger Agreement\"), among Andor LLC, Andor Merger Co., the Issuer and AbbVie Inc."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reported securities represent shares of the Issuer's common stock disposed of pursuant to the terms of the Agreement and Plan of Merger, dated as of June 18, 2026 (the \"Merger Agreement\"), among Andor LLC, Andor Merger Co., the Issuer and AbbVie Inc."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001140361-26-035614","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1974640/000114036126035614/form4.xml","form_type":"4"}},{"id":698905,"issuer":{"id":4910,"kind":"organization","name":"Apnimed, Inc."},"owners":[{"id":1941,"kind":"person","name":"JONES WILLIAM A JR","position":1,"cik":"0001373097","reported_name":"JONES WILLIAM A JR","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-08-03T20:01:05.000Z","date":"2026-08-03","kind":"grant","planned":false,"acquired":true,"shares":44477,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Class A Common Stock was reclassified into one share of Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to such option vest and become exercisable in substantially equal monthly installments for a period of 36 months after July 30, 2026, subject to the Reporting Person's continuous service to the Issuer on each such date."}],"balance_after":44477,"derivative":{"exercise_price":16,"expiration_date":"2036-07-29","underlying":"Common Stock","underlying_shares":44477},"source":{"system":"sec-edgar","filing":"0001193125-26-330503","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1745648/000119312526330503/ownership.xml","form_type":"4"}},{"id":698904,"issuer":{"id":4910,"kind":"organization","name":"Apnimed, Inc."},"owners":[{"id":1941,"kind":"person","name":"JONES WILLIAM A JR","position":1,"cik":"0001373097","reported_name":"JONES WILLIAM A JR","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-08-03T20:01:05.000Z","date":"2026-08-03","kind":"disposition_to_issuer","planned":false,"acquired":true,"shares":44477,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Class A Common Stock was reclassified into one share of Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to such option vest and become exercisable in substantially equal monthly installments for a period of 36 months after July 30, 2026, subject to the Reporting Person's continuous service to the Issuer on each such date."}],"balance_after":0,"derivative":{"exercise_price":16,"expiration_date":"2036-07-29","underlying":"Class A Common Stock","underlying_shares":44477},"source":{"system":"sec-edgar","filing":"0001193125-26-330503","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1745648/000119312526330503/ownership.xml","form_type":"4"}},{"id":698903,"issuer":{"id":4910,"kind":"organization","name":"Apnimed, Inc."},"owners":[{"id":1941,"kind":"person","name":"JONES WILLIAM A JR","position":1,"cik":"0001373097","reported_name":"JONES WILLIAM A JR","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-08-03T20:01:05.000Z","date":"2026-07-30","kind":"grant","planned":false,"acquired":true,"shares":44477,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to such option vest and become exercisable in substantially equal monthly installments for a period of 36 months after July 30, 2026, subject to the Reporting Person's continuous service to the Issuer on each such date."}],"balance_after":44477,"derivative":{"exercise_price":16,"expiration_date":"2036-07-29","underlying":"Class A Common Stock","underlying_shares":44477},"source":{"system":"sec-edgar","filing":"0001193125-26-330503","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1745648/000119312526330503/ownership.xml","form_type":"4"}},{"id":737543,"issuer":{"id":5011,"kind":"organization","name":"Annexon, Inc.","symbol":"ANNX"},"owners":[{"id":1941,"kind":"person","name":"JONES WILLIAM A JR","position":1,"cik":"0001373097","reported_name":"JONES WILLIAM A JR","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-15T20:15:19.000Z","date":"2026-06-11","kind":"grant","planned":false,"acquired":true,"shares":65000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of June 11, 2026 or (ii) the next Annual Meeting following June 11, 2026, subject to Reporting Person's continuous service as a director until such vesting date."}],"balance_after":65000,"derivative":{"exercise_price":4.7,"expiration_date":"2036-06-11","underlying":"Common Stock","underlying_shares":65000},"source":{"system":"sec-edgar","filing":"0001373097-26-000001","document":"form4-06152026_040609.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1373097/000137309726000001/form4-06152026_040609.xml","form_type":"4"}},{"id":741280,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":1941,"kind":"person","name":"JONES WILLIAM A JR","position":1,"cik":"0001373097","reported_name":"JONES WILLIAM A JR","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-12T00:02:30.000Z","date":"2026-06-09","kind":"grant","planned":false,"acquired":true,"shares":7657,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option represents the right to purchase 7,657 shares of the Issuer's common stock and will vest on the one-year anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer on such vesting date."}],"balance_after":7657,"derivative":{"exercise_price":85,"expiration_date":"2036-06-09","underlying":"Common Stock","underlying_shares":7657},"source":{"system":"sec-edgar","filing":"0001104659-26-073059","document":"tm2617578-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1373097/000110465926073059/tm2617578-1_4seq1.xml","form_type":"4"}},{"id":1104740,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":1941,"kind":"person","name":"JONES WILLIAM A JR","position":1,"cik":"0001373097","reported_name":"JONES WILLIAM A JR","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-21T00:03:24.000Z","date":"2025-06-17","kind":"grant","planned":false,"acquired":true,"shares":14461,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option represents the right to purchase 14,461 shares of the Issuer's common stock and will vest on the one-year anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer on such vesting date."}],"balance_after":14461,"derivative":{"exercise_price":41.66,"expiration_date":"2035-06-17","underlying":"Common Stock","underlying_shares":14461},"source":{"system":"sec-edgar","filing":"0001104659-25-061275","document":"tm2518364-7_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1373097/000110465925061275/tm2518364-7_4seq1.xml","form_type":"4"}},{"id":1117527,"issuer":{"id":5011,"kind":"organization","name":"Annexon, Inc.","symbol":"ANNX"},"owners":[{"id":1941,"kind":"person","name":"JONES WILLIAM A JR","position":1,"cik":"0001373097","reported_name":"JONES WILLIAM A JR","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-09T20:17:54.000Z","date":"2025-06-05","kind":"grant","planned":false,"acquired":true,"shares":55000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of June 5, 2025 or (ii) the next Annual Meeting following June 5, 2025, subject to Reporting Person's continuous service as a director until such vesting date."}],"balance_after":55000,"derivative":{"exercise_price":2.55,"expiration_date":"2035-06-05","underlying":"Common Stock","underlying_shares":55000},"source":{"system":"sec-edgar","filing":"0001415889-25-016243","document":"form4-06092025_080648.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1373097/000141588925016243/form4-06092025_080648.xml","form_type":"4"}},{"id":1304970,"issuer":{"id":5011,"kind":"organization","name":"Annexon, Inc.","symbol":"ANNX"},"owners":[{"id":1941,"kind":"person","name":"JONES WILLIAM A JR","position":1,"cik":"0001373097","reported_name":"JONES WILLIAM A JR","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-01-10T23:02:23.000Z","date":"2025-01-09","kind":"grant","planned":false,"acquired":true,"shares":88000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/36th of the shares subject to the option vest on each monthly anniversary measured from January 9, 2025 (the \"Vesting Commencement Date\"), such that 100% of the shares subject to the option will be fully vested and exercisable on the third anniversary of the Vesting Commencement Date."}],"balance_after":88000,"derivative":{"exercise_price":4.83,"expiration_date":"2035-01-09","underlying":"Common Stock","underlying_shares":88000},"source":{"system":"sec-edgar","filing":"0001415889-25-001308","document":"form4-01102025_110119.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1373097/000141588925001308/form4-01102025_110119.xml","form_type":"4"}},{"id":1308333,"issuer":{"id":1826,"kind":"organization","name":"NewAmsterdam Pharma Co N.V.","symbol":"NAMS"},"owners":[{"id":1941,"kind":"person","name":"JONES WILLIAM A JR","position":1,"cik":"0001373097","reported_name":"JONES WILLIAM A JR","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Ordinary Shares","published_at":"2025-01-07T22:12:26.000Z","date":"2025-01-07","kind":"grant","planned":false,"acquired":true,"shares":43000,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units (RSUs), each representing a contingent right to receive one ordinary share. 1/3 of the RSUs will vest on each of the first, second and third anniversaries of the vesting start date, subject to the Reporting Person's continued service through each such date."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each RSU was granted on January 7, 2025 for no consideration."}],"balance_after":43000,"source":{"system":"sec-edgar","filing":"0000950170-25-002988","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1936258/000095017025002988/ownership.xml","form_type":"4"}},{"id":1311139,"issuer":{"id":1826,"kind":"organization","name":"NewAmsterdam Pharma Co N.V.","symbol":"NAMS"},"owners":[{"id":1941,"kind":"person","name":"JONES WILLIAM A JR","position":1,"cik":"0001373097","reported_name":"JONES WILLIAM A JR","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Option (right to buy)","published_at":"2025-01-06T22:51:22.000Z","date":"2025-01-02","kind":"grant","planned":false,"acquired":true,"shares":200000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares underlying the option will vest on January 2, 2026, the one-year anniversary of vesting start date, with the remaining shares vesting in equal monthly installments thereafter for three years, subject to the Reporting Person's continued service through each such date."}],"balance_after":200000,"derivative":{"exercise_price":25.96,"expiration_date":"2035-01-02","underlying":"Ordinary Shares","underlying_shares":200000},"source":{"system":"sec-edgar","filing":"0000950170-25-002363","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1936258/000095017025002363/ownership.xml","form_type":"4"}},{"id":1486302,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":1941,"kind":"person","name":"JONES WILLIAM A JR","position":1,"cik":"0001373097","reported_name":"JONES WILLIAM A JR","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-08T00:12:41.000Z","date":"2024-06-05","kind":"grant","planned":false,"acquired":true,"shares":10370,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option represents the right to purchase 10,370 shares of the Issuer's common stock and will vest on the one-year anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer on such vesting date."}],"balance_after":10370,"derivative":{"exercise_price":43.85,"expiration_date":"2034-06-05","underlying":"Common Stock","underlying_shares":10370},"source":{"system":"sec-edgar","filing":"0001104659-24-069803","document":"tm2416491-4_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1373097/000110465924069803/tm2416491-4_4seq1.xml","form_type":"4"}},{"id":1904580,"issuer":{"id":89130,"kind":"organization","name":"Akili, Inc.","symbol":"AKLI"},"owners":[{"id":1941,"kind":"person","name":"JONES WILLIAM A JR","position":1,"cik":"0001373097","reported_name":"JONES WILLIAM A JR","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-05-04T16:20:34.000Z","date":"2023-05-02","kind":"grant","planned":false,"acquired":true,"shares":22000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this option shall vest in full upon the earlier of (i) May 2, 2024 or (ii) the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service at such time."}],"balance_after":22000,"derivative":{"exercise_price":1.09,"expiration_date":"2033-05-02","underlying":"Common Stock","underlying_shares":22000},"source":{"system":"sec-edgar","filing":"0000899243-23-012262","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1850266/000089924323012262/doc4.xml","form_type":"4"}},{"id":2124560,"issuer":{"id":89130,"kind":"organization","name":"Akili, Inc.","symbol":"AKLI"},"owners":[{"id":1941,"kind":"person","name":"JONES WILLIAM A JR","position":1,"cik":"0001373097","reported_name":"JONES WILLIAM A JR","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-11-04T18:58:39.000Z","date":"2022-11-02","kind":"grant","acquired":true,"shares":44000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this option shall vest and become exercisable in three (3) equal annual installments on each of the first three anniversaries of November 2, 2022, the date of grant, subject to the reporting person's continued service on each such vesting date."}],"balance_after":44000,"derivative":{"exercise_price":2.3,"expiration_date":"2032-11-02","underlying":"Common Stock","underlying_shares":44000},"source":{"system":"sec-edgar","filing":"0000899243-22-035242","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1850266/000089924322035242/doc4.xml","form_type":"4"}},{"id":2147430,"issuer":{"id":123269,"kind":"organization","name":"Biohaven Pharmaceutical Holding Co Ltd."},"owners":[{"id":1941,"kind":"person","name":"JONES WILLIAM A JR","position":1,"cik":"0001373097","reported_name":"JONES WILLIAM A JR","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CCO-Migraine & Common Disease"}}],"security":"Stock Options (Right to Buy)","published_at":"2022-10-03T20:25:52.000Z","date":"2022-10-03","kind":"disposition_to_issuer","acquired":false,"shares":44087,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a \"Post-Spin Issuer Option\"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes."},{"field":"shares","element":"transactionShares","label":"F4","text":"In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a \"Post-Spin Issuer Option\"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a \"Post-Spin Issuer Option\"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a \"Post-Spin Issuer Option\"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a \"Post-Spin Issuer Option\"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes."}],"balance_after":0,"derivative":{"exercise_price":49.47,"expiration_date":"2029-04-01","underlying":"Common Shares","underlying_shares":44087},"source":{"system":"sec-edgar","filing":"0001562180-22-006962","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1689813/000156218022006962/primarydocument.xml","form_type":"4"}},{"id":2147429,"issuer":{"id":123269,"kind":"organization","name":"Biohaven Pharmaceutical Holding Co Ltd."},"owners":[{"id":1941,"kind":"person","name":"JONES WILLIAM A JR","position":1,"cik":"0001373097","reported_name":"JONES WILLIAM A JR","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CCO-Migraine & Common Disease"}}],"security":"Stock Options (Right to Buy)","published_at":"2022-10-03T20:25:52.000Z","date":"2022-10-03","kind":"disposition_to_issuer","acquired":false,"shares":5913,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a \"Post-Spin Issuer Option\"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a \"Post-Spin Issuer Option\"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a \"Post-Spin Issuer Option\"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a \"Post-Spin Issuer Option\"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes."}],"balance_after":0,"derivative":{"exercise_price":49.47,"expiration_date":"2029-04-01","underlying":"Common Shares","underlying_shares":5913},"source":{"system":"sec-edgar","filing":"0001562180-22-006962","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1689813/000156218022006962/primarydocument.xml","form_type":"4"}},{"id":2147428,"issuer":{"id":123269,"kind":"organization","name":"Biohaven Pharmaceutical Holding Co Ltd."},"owners":[{"id":1941,"kind":"person","name":"JONES WILLIAM A JR","position":1,"cik":"0001373097","reported_name":"JONES WILLIAM A JR","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CCO-Migraine & Common Disease"}}],"security":"Stock Options (Right to Buy)","published_at":"2022-10-03T20:25:52.000Z","date":"2022-10-03","kind":"disposition_to_issuer","acquired":false,"shares":28258,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a \"Post-Spin Issuer Option\"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes."},{"field":"shares","element":"transactionShares","label":"F4","text":"In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a \"Post-Spin Issuer Option\"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a \"Post-Spin Issuer Option\"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a \"Post-Spin Issuer Option\"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a \"Post-Spin Issuer Option\"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes."}],"balance_after":0,"derivative":{"exercise_price":55.99,"expiration_date":"2029-11-25","underlying":"Common Shares","underlying_shares":28258},"source":{"system":"sec-edgar","filing":"0001562180-22-006962","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1689813/000156218022006962/primarydocument.xml","form_type":"4"}},{"id":2147427,"issuer":{"id":123269,"kind":"organization","name":"Biohaven Pharmaceutical Holding Co Ltd."},"owners":[{"id":1941,"kind":"person","name":"JONES WILLIAM A JR","position":1,"cik":"0001373097","reported_name":"JONES WILLIAM A JR","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CCO-Migraine & Common Disease"}}],"security":"Stock Options (Right to Buy)","published_at":"2022-10-03T20:25:52.000Z","date":"2022-10-03","kind":"disposition_to_issuer","acquired":false,"shares":1742,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a \"Post-Spin Issuer Option\"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes."},{"field":"shares","element":"transactionShares","label":"F4","text":"In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a \"Post-Spin Issuer Option\"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a \"Post-Spin Issuer Option\"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a \"Post-Spin Issuer Option\"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a \"Post-Spin Issuer Option\"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes."}],"balance_after":0,"derivative":{"exercise_price":55.99,"expiration_date":"2029-11-25","underlying":"Common Shares","underlying_shares":1742},"source":{"system":"sec-edgar","filing":"0001562180-22-006962","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1689813/000156218022006962/primarydocument.xml","form_type":"4"}},{"id":2147426,"issuer":{"id":123269,"kind":"organization","name":"Biohaven Pharmaceutical Holding Co Ltd."},"owners":[{"id":1941,"kind":"person","name":"JONES WILLIAM A JR","position":1,"cik":"0001373097","reported_name":"JONES WILLIAM A JR","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CCO-Migraine & Common Disease"}}],"security":"Stock Options (Right to Buy)","published_at":"2022-10-03T20:25:52.000Z","date":"2022-10-03","kind":"disposition_to_issuer","acquired":false,"shares":37602,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a \"Post-Spin Issuer Option\"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes."},{"field":"shares","element":"transactionShares","label":"F4","text":"In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a \"Post-Spin Issuer Option\"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a \"Post-Spin Issuer Option\"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a \"Post-Spin Issuer Option\"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a \"Post-Spin Issuer Option\"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes."}],"balance_after":0,"derivative":{"exercise_price":81.32,"expiration_date":"2031-01-06","underlying":"Common Shares","underlying_shares":37602},"source":{"system":"sec-edgar","filing":"0001562180-22-006962","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1689813/000156218022006962/primarydocument.xml","form_type":"4"}},{"id":2147425,"issuer":{"id":123269,"kind":"organization","name":"Biohaven Pharmaceutical Holding Co Ltd."},"owners":[{"id":1941,"kind":"person","name":"JONES WILLIAM A JR","position":1,"cik":"0001373097","reported_name":"JONES WILLIAM A JR","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CCO-Migraine & Common Disease"}}],"security":"Stock Options (Right to Buy)","published_at":"2022-10-03T20:25:52.000Z","date":"2022-10-03","kind":"disposition_to_issuer","acquired":false,"shares":2398,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a \"Post-Spin Issuer Option\"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes."},{"field":"shares","element":"transactionShares","label":"F4","text":"In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a \"Post-Spin Issuer Option\"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a \"Post-Spin Issuer Option\"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a \"Post-Spin Issuer Option\"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a \"Post-Spin Issuer Option\"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes."}],"balance_after":0,"derivative":{"exercise_price":81.32,"expiration_date":"2031-01-06","underlying":"Common Shares","underlying_shares":2398},"source":{"system":"sec-edgar","filing":"0001562180-22-006962","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1689813/000156218022006962/primarydocument.xml","form_type":"4"}},{"id":2147424,"issuer":{"id":123269,"kind":"organization","name":"Biohaven Pharmaceutical Holding Co Ltd."},"owners":[{"id":1941,"kind":"person","name":"JONES WILLIAM A JR","position":1,"cik":"0001373097","reported_name":"JONES WILLIAM A JR","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CCO-Migraine & Common Disease"}}],"security":"Stock Options (Right to Buy)","published_at":"2022-10-03T20:25:52.000Z","date":"2022-10-03","kind":"disposition_to_issuer","acquired":false,"shares":29225,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a \"Post-Spin Issuer Option\"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes."},{"field":"shares","element":"transactionShares","label":"F4","text":"In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a \"Post-Spin Issuer Option\"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a \"Post-Spin Issuer Option\"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a \"Post-Spin Issuer Option\"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a \"Post-Spin Issuer Option\"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes."}],"balance_after":0,"derivative":{"exercise_price":125.69,"expiration_date":"2032-01-07","underlying":"Common Shares","underlying_shares":29225},"source":{"system":"sec-edgar","filing":"0001562180-22-006962","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1689813/000156218022006962/primarydocument.xml","form_type":"4"}},{"id":2147423,"issuer":{"id":123269,"kind":"organization","name":"Biohaven Pharmaceutical Holding Co Ltd."},"owners":[{"id":1941,"kind":"person","name":"JONES WILLIAM A JR","position":1,"cik":"0001373097","reported_name":"JONES WILLIAM A JR","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CCO-Migraine & Common Disease"}}],"security":"Stock Options (Right to Buy)","published_at":"2022-10-03T20:25:52.000Z","date":"2022-10-03","kind":"disposition_to_issuer","acquired":false,"shares":775,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a \"Post-Spin Issuer Option\"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes."},{"field":"shares","element":"transactionShares","label":"F4","text":"In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a \"Post-Spin Issuer Option\"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a \"Post-Spin Issuer Option\"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a \"Post-Spin Issuer Option\"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a \"Post-Spin Issuer Option\"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes."}],"balance_after":0,"derivative":{"exercise_price":125.69,"expiration_date":"2032-01-07","underlying":"Common Shares","underlying_shares":775},"source":{"system":"sec-edgar","filing":"0001562180-22-006962","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1689813/000156218022006962/primarydocument.xml","form_type":"4"}},{"id":2147422,"issuer":{"id":123269,"kind":"organization","name":"Biohaven Pharmaceutical Holding Co Ltd."},"owners":[{"id":1941,"kind":"person","name":"JONES WILLIAM A JR","position":1,"cik":"0001373097","reported_name":"JONES WILLIAM A JR","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CCO-Migraine & Common Disease"}}],"security":"Restricted Share Unit Award","published_at":"2022-10-03T20:25:52.000Z","date":"2022-10-03","kind":"disposition_to_issuer","acquired":false,"shares":3000,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"In connection with the distribution (\"Distribution\") by the Issuer to holders of its common shares of all the outstanding common shares of Biohaven Ltd. (\"SpinCo\"), each outstanding restricted share unit of the Issuer was adjusted such that such restricted share unit became a restricted share unit in respect of common shares of SpinCo and a restricted share unit in respect of Common Shares (each such restricted share unit, a \"Post-Spin Issuer RSU\"). At the effective time of the Merger, each outstanding Post-Spin Issuer RSU was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the number of Common Shares subject to such Post-Spin Issuer RSU, with any performance conditions applicable to such Post-Spin Issuer RSU deemed achieved at 100%, and (ii) the Merger Consideration, less any withholding taxes."},{"field":"shares","element":"transactionShares","label":"F3","text":"In connection with the distribution (\"Distribution\") by the Issuer to holders of its common shares of all the outstanding common shares of Biohaven Ltd. (\"SpinCo\"), each outstanding restricted share unit of the Issuer was adjusted such that such restricted share unit became a restricted share unit in respect of common shares of SpinCo and a restricted share unit in respect of Common Shares (each such restricted share unit, a \"Post-Spin Issuer RSU\"). At the effective time of the Merger, each outstanding Post-Spin Issuer RSU was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the number of Common Shares subject to such Post-Spin Issuer RSU, with any performance conditions applicable to such Post-Spin Issuer RSU deemed achieved at 100%, and (ii) the Merger Consideration, less any withholding taxes."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"In connection with the distribution (\"Distribution\") by the Issuer to holders of its common shares of all the outstanding common shares of Biohaven Ltd. (\"SpinCo\"), each outstanding restricted share unit of the Issuer was adjusted such that such restricted share unit became a restricted share unit in respect of common shares of SpinCo and a restricted share unit in respect of Common Shares (each such restricted share unit, a \"Post-Spin Issuer RSU\"). At the effective time of the Merger, each outstanding Post-Spin Issuer RSU was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the number of Common Shares subject to such Post-Spin Issuer RSU, with any performance conditions applicable to such Post-Spin Issuer RSU deemed achieved at 100%, and (ii) the Merger Consideration, less any withholding taxes."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"In connection with the distribution (\"Distribution\") by the Issuer to holders of its common shares of all the outstanding common shares of Biohaven Ltd. (\"SpinCo\"), each outstanding restricted share unit of the Issuer was adjusted such that such restricted share unit became a restricted share unit in respect of common shares of SpinCo and a restricted share unit in respect of Common Shares (each such restricted share unit, a \"Post-Spin Issuer RSU\"). At the effective time of the Merger, each outstanding Post-Spin Issuer RSU was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the number of Common Shares subject to such Post-Spin Issuer RSU, with any performance conditions applicable to such Post-Spin Issuer RSU deemed achieved at 100%, and (ii) the Merger Consideration, less any withholding taxes."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"In connection with the distribution (\"Distribution\") by the Issuer to holders of its common shares of all the outstanding common shares of Biohaven Ltd. (\"SpinCo\"), each outstanding restricted share unit of the Issuer was adjusted such that such restricted share unit became a restricted share unit in respect of common shares of SpinCo and a restricted share unit in respect of Common Shares (each such restricted share unit, a \"Post-Spin Issuer RSU\"). At the effective time of the Merger, each outstanding Post-Spin Issuer RSU was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the number of Common Shares subject to such Post-Spin Issuer RSU, with any performance conditions applicable to such Post-Spin Issuer RSU deemed achieved at 100%, and (ii) the Merger Consideration, less any withholding taxes."}],"balance_after":0,"derivative":{"underlying":"Common Shares","underlying_shares":3000},"source":{"system":"sec-edgar","filing":"0001562180-22-006962","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1689813/000156218022006962/primarydocument.xml","form_type":"4"}},{"id":2147421,"issuer":{"id":123269,"kind":"organization","name":"Biohaven Pharmaceutical Holding Co Ltd."},"owners":[{"id":1941,"kind":"person","name":"JONES WILLIAM A JR","position":1,"cik":"0001373097","reported_name":"JONES WILLIAM A JR","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CCO-Migraine & Common Disease"}}],"security":"Restricted Share Unit Award","published_at":"2022-10-03T20:25:52.000Z","date":"2022-10-03","kind":"disposition_to_issuer","acquired":false,"shares":10000,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"In connection with the distribution (\"Distribution\") by the Issuer to holders of its common shares of all the outstanding common shares of Biohaven Ltd. (\"SpinCo\"), each outstanding restricted share unit of the Issuer was adjusted such that such restricted share unit became a restricted share unit in respect of common shares of SpinCo and a restricted share unit in respect of Common Shares (each such restricted share unit, a \"Post-Spin Issuer RSU\"). At the effective time of the Merger, each outstanding Post-Spin Issuer RSU was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the number of Common Shares subject to such Post-Spin Issuer RSU, with any performance conditions applicable to such Post-Spin Issuer RSU deemed achieved at 100%, and (ii) the Merger Consideration, less any withholding taxes."},{"field":"shares","element":"transactionShares","label":"F3","text":"In connection with the distribution (\"Distribution\") by the Issuer to holders of its common shares of all the outstanding common shares of Biohaven Ltd. (\"SpinCo\"), each outstanding restricted share unit of the Issuer was adjusted such that such restricted share unit became a restricted share unit in respect of common shares of SpinCo and a restricted share unit in respect of Common Shares (each such restricted share unit, a \"Post-Spin Issuer RSU\"). At the effective time of the Merger, each outstanding Post-Spin Issuer RSU was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the number of Common Shares subject to such Post-Spin Issuer RSU, with any performance conditions applicable to such Post-Spin Issuer RSU deemed achieved at 100%, and (ii) the Merger Consideration, less any withholding taxes."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"In connection with the distribution (\"Distribution\") by the Issuer to holders of its common shares of all the outstanding common shares of Biohaven Ltd. (\"SpinCo\"), each outstanding restricted share unit of the Issuer was adjusted such that such restricted share unit became a restricted share unit in respect of common shares of SpinCo and a restricted share unit in respect of Common Shares (each such restricted share unit, a \"Post-Spin Issuer RSU\"). At the effective time of the Merger, each outstanding Post-Spin Issuer RSU was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the number of Common Shares subject to such Post-Spin Issuer RSU, with any performance conditions applicable to such Post-Spin Issuer RSU deemed achieved at 100%, and (ii) the Merger Consideration, less any withholding taxes."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"In connection with the distribution (\"Distribution\") by the Issuer to holders of its common shares of all the outstanding common shares of Biohaven Ltd. (\"SpinCo\"), each outstanding restricted share unit of the Issuer was adjusted such that such restricted share unit became a restricted share unit in respect of common shares of SpinCo and a restricted share unit in respect of Common Shares (each such restricted share unit, a \"Post-Spin Issuer RSU\"). At the effective time of the Merger, each outstanding Post-Spin Issuer RSU was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the number of Common Shares subject to such Post-Spin Issuer RSU, with any performance conditions applicable to such Post-Spin Issuer RSU deemed achieved at 100%, and (ii) the Merger Consideration, less any withholding taxes."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"In connection with the distribution (\"Distribution\") by the Issuer to holders of its common shares of all the outstanding common shares of Biohaven Ltd. (\"SpinCo\"), each outstanding restricted share unit of the Issuer was adjusted such that such restricted share unit became a restricted share unit in respect of common shares of SpinCo and a restricted share unit in respect of Common Shares (each such restricted share unit, a \"Post-Spin Issuer RSU\"). At the effective time of the Merger, each outstanding Post-Spin Issuer RSU was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the number of Common Shares subject to such Post-Spin Issuer RSU, with any performance conditions applicable to such Post-Spin Issuer RSU deemed achieved at 100%, and (ii) the Merger Consideration, less any withholding taxes."}],"balance_after":0,"derivative":{"underlying":"Common Shares","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001562180-22-006962","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1689813/000156218022006962/primarydocument.xml","form_type":"4"}},{"id":2147420,"issuer":{"id":123269,"kind":"organization","name":"Biohaven Pharmaceutical Holding Co Ltd."},"owners":[{"id":1941,"kind":"person","name":"JONES WILLIAM A JR","position":1,"cik":"0001373097","reported_name":"JONES WILLIAM A JR","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CCO-Migraine & Common Disease"}}],"security":"Restricted Share Unit Award","published_at":"2022-10-03T20:25:52.000Z","date":"2022-10-03","kind":"disposition_to_issuer","acquired":false,"shares":11250,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"In connection with the distribution (\"Distribution\") by the Issuer to holders of its common shares of all the outstanding common shares of Biohaven Ltd. (\"SpinCo\"), each outstanding restricted share unit of the Issuer was adjusted such that such restricted share unit became a restricted share unit in respect of common shares of SpinCo and a restricted share unit in respect of Common Shares (each such restricted share unit, a \"Post-Spin Issuer RSU\"). At the effective time of the Merger, each outstanding Post-Spin Issuer RSU was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the number of Common Shares subject to such Post-Spin Issuer RSU, with any performance conditions applicable to such Post-Spin Issuer RSU deemed achieved at 100%, and (ii) the Merger Consideration, less any withholding taxes."},{"field":"shares","element":"transactionShares","label":"F3","text":"In connection with the distribution (\"Distribution\") by the Issuer to holders of its common shares of all the outstanding common shares of Biohaven Ltd. (\"SpinCo\"), each outstanding restricted share unit of the Issuer was adjusted such that such restricted share unit became a restricted share unit in respect of common shares of SpinCo and a restricted share unit in respect of Common Shares (each such restricted share unit, a \"Post-Spin Issuer RSU\"). At the effective time of the Merger, each outstanding Post-Spin Issuer RSU was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the number of Common Shares subject to such Post-Spin Issuer RSU, with any performance conditions applicable to such Post-Spin Issuer RSU deemed achieved at 100%, and (ii) the Merger Consideration, less any withholding taxes."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"In connection with the distribution (\"Distribution\") by the Issuer to holders of its common shares of all the outstanding common shares of Biohaven Ltd. (\"SpinCo\"), each outstanding restricted share unit of the Issuer was adjusted such that such restricted share unit became a restricted share unit in respect of common shares of SpinCo and a restricted share unit in respect of Common Shares (each such restricted share unit, a \"Post-Spin Issuer RSU\"). At the effective time of the Merger, each outstanding Post-Spin Issuer RSU was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the number of Common Shares subject to such Post-Spin Issuer RSU, with any performance conditions applicable to such Post-Spin Issuer RSU deemed achieved at 100%, and (ii) the Merger Consideration, less any withholding taxes."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"In connection with the distribution (\"Distribution\") by the Issuer to holders of its common shares of all the outstanding common shares of Biohaven Ltd. (\"SpinCo\"), each outstanding restricted share unit of the Issuer was adjusted such that such restricted share unit became a restricted share unit in respect of common shares of SpinCo and a restricted share unit in respect of Common Shares (each such restricted share unit, a \"Post-Spin Issuer RSU\"). At the effective time of the Merger, each outstanding Post-Spin Issuer RSU was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the number of Common Shares subject to such Post-Spin Issuer RSU, with any performance conditions applicable to such Post-Spin Issuer RSU deemed achieved at 100%, and (ii) the Merger Consideration, less any withholding taxes."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"In connection with the distribution (\"Distribution\") by the Issuer to holders of its common shares of all the outstanding common shares of Biohaven Ltd. (\"SpinCo\"), each outstanding restricted share unit of the Issuer was adjusted such that such restricted share unit became a restricted share unit in respect of common shares of SpinCo and a restricted share unit in respect of Common Shares (each such restricted share unit, a \"Post-Spin Issuer RSU\"). At the effective time of the Merger, each outstanding Post-Spin Issuer RSU was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the number of Common Shares subject to such Post-Spin Issuer RSU, with any performance conditions applicable to such Post-Spin Issuer RSU deemed achieved at 100%, and (ii) the Merger Consideration, less any withholding taxes."}],"balance_after":0,"derivative":{"underlying":"Common Shares","underlying_shares":11250},"source":{"system":"sec-edgar","filing":"0001562180-22-006962","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1689813/000156218022006962/primarydocument.xml","form_type":"4"}},{"id":2147419,"issuer":{"id":123269,"kind":"organization","name":"Biohaven Pharmaceutical Holding Co Ltd."},"owners":[{"id":1941,"kind":"person","name":"JONES WILLIAM A JR","position":1,"cik":"0001373097","reported_name":"JONES WILLIAM A JR","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CCO-Migraine & Common Disease"}}],"security":"Common Shares","published_at":"2022-10-03T20:25:52.000Z","date":"2022-10-03","kind":"disposition_to_issuer","acquired":false,"shares":14226,"price":148.5,"value":2112561.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Under the Agreement and Plan of Merger, dated as of May 9, 2022 (the \"Merger Agreement\"), by and among the Issuer, Pfizer Inc. (\"Pfizer\") and a wholly owned subsidiary of Pfizer (\"Merger Sub\"), following satisfaction or waiver of the closing conditions set forth in the Merger Agreement, on October 3, 2022 Merger Sub merged with and into the Issuer with the Issuer surviving as the surviving company (the \"Merger\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In the Merger, each common share of the Issuer (each, a \"Common Share\") outstanding immediately prior to the effective time of the Merger (other than certain excluded shares pursuant to the terms of the Merger Agreement), was converted into the right to receive the merger consideration in cash of $148.50, without interest, less any withholding taxes (the \"Merger Consideration\")."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001562180-22-006962","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1689813/000156218022006962/primarydocument.xml","form_type":"4"}},{"id":2440077,"issuer":{"id":123269,"kind":"organization","name":"Biohaven Pharmaceutical Holding Co Ltd."},"owners":[{"id":1941,"kind":"person","name":"JONES WILLIAM A JR","position":1,"cik":"0001373097","reported_name":"JONES WILLIAM A JR","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CCO-Migraine & Common Disease"}}],"security":"Restricted Share Unit Award","published_at":"2022-01-07T21:16:53.000Z","date":"2022-01-07","kind":"exercise","acquired":false,"shares":3750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each restricted share unit represents the contingent right to receive one common share of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The reporting person was granted 15,000 restricted share units on January 7, 2022, vesting in four equal installments on January 7, 2022, 2023, 2024 and 2025, subject to the reporting person's continued service with the Issuer at each vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Not applicable."}],"balance_after":11250,"derivative":{"underlying":"Common Shares","underlying_shares":3750},"source":{"system":"sec-edgar","filing":"0001562180-22-000351","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1689813/000156218022000351/primarydocument.xml","form_type":"4"}},{"id":2440076,"issuer":{"id":123269,"kind":"organization","name":"Biohaven Pharmaceutical Holding Co Ltd."},"owners":[{"id":1941,"kind":"person","name":"JONES WILLIAM A JR","position":1,"cik":"0001373097","reported_name":"JONES WILLIAM A JR","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CCO-Migraine & Common Disease"}}],"security":"Restricted Share Unit Award","published_at":"2022-01-07T21:16:53.000Z","date":"2022-01-07","kind":"grant","acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each restricted share unit represents the contingent right to receive one common share of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The reporting person was granted 15,000 restricted share units on January 7, 2022, vesting in four equal installments on January 7, 2022, 2023, 2024 and 2025, subject to the reporting person's continued service with the Issuer at each vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Not applicable."}],"balance_after":15000,"derivative":{"underlying":"Common Shares","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001562180-22-000351","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1689813/000156218022000351/primarydocument.xml","form_type":"4"}},{"id":2440075,"issuer":{"id":123269,"kind":"organization","name":"Biohaven Pharmaceutical Holding Co Ltd."},"owners":[{"id":1941,"kind":"person","name":"JONES WILLIAM A JR","position":1,"cik":"0001373097","reported_name":"JONES WILLIAM A JR","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CCO-Migraine & Common Disease"}}],"security":"Employee Stock Option (right to buy)","published_at":"2022-01-07T21:16:53.000Z","date":"2022-01-07","kind":"grant","acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The shares underlying this option vest in four equal installments on January 7, 2022, 2023, 2024 and 2025, subject to the reporting person's continuous service with the Issuer at each vesting date."}],"balance_after":30000,"derivative":{"exercise_price":128.87,"expiration_date":"2032-01-07","underlying":"Common Shares","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001562180-22-000351","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1689813/000156218022000351/primarydocument.xml","form_type":"4"}},{"id":2440074,"issuer":{"id":123269,"kind":"organization","name":"Biohaven Pharmaceutical Holding Co Ltd."},"owners":[{"id":1941,"kind":"person","name":"JONES WILLIAM A JR","position":1,"cik":"0001373097","reported_name":"JONES WILLIAM A JR","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CCO-Migraine & Common Disease"}}],"security":"Restricted Share Unit Award","published_at":"2022-01-07T21:16:53.000Z","date":"2022-01-06","kind":"exercise","acquired":false,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each restricted share unit represents the contingent right to receive one common share of the Issuer."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Each restricted share unit represents the contingent right to receive one common share of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The reporting person was granted 20,000 restricted share units on January 6, 2021, vesting in four equal installments on January 6, 2021, 2022, 2023 and 2024, subject to the reporting person's continued service with the Issuer at each vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Not applicable."}],"balance_after":10000,"derivative":{"underlying":"Common Shares","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0001562180-22-000351","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1689813/000156218022000351/primarydocument.xml","form_type":"4"}},{"id":2440073,"issuer":{"id":123269,"kind":"organization","name":"Biohaven Pharmaceutical Holding Co Ltd."},"owners":[{"id":1941,"kind":"person","name":"JONES WILLIAM A JR","position":1,"cik":"0001373097","reported_name":"JONES WILLIAM A JR","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CCO-Migraine & Common Disease"}}],"security":"Common Shares","published_at":"2022-01-07T21:16:53.000Z","date":"2022-01-07","kind":"tax_withholding","acquired":false,"shares":1631,"price":128.87,"value":210186.97,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"No shares were sold - these shares were withheld by the Issuer to satisfy tax withholding requirements in connection with the vesting of restricted share units."}],"balance_after":13999,"source":{"system":"sec-edgar","filing":"0001562180-22-000351","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1689813/000156218022000351/primarydocument.xml","form_type":"4"}},{"id":2440072,"issuer":{"id":123269,"kind":"organization","name":"Biohaven Pharmaceutical Holding Co Ltd."},"owners":[{"id":1941,"kind":"person","name":"JONES WILLIAM A JR","position":1,"cik":"0001373097","reported_name":"JONES WILLIAM A JR","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CCO-Migraine & Common Disease"}}],"security":"Common Shares","published_at":"2022-01-07T21:16:53.000Z","date":"2022-01-07","kind":"exercise","acquired":true,"shares":3750,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":15630,"source":{"system":"sec-edgar","filing":"0001562180-22-000351","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1689813/000156218022000351/primarydocument.xml","form_type":"4"}},{"id":2440071,"issuer":{"id":123269,"kind":"organization","name":"Biohaven Pharmaceutical Holding Co Ltd."},"owners":[{"id":1941,"kind":"person","name":"JONES WILLIAM A JR","position":1,"cik":"0001373097","reported_name":"JONES WILLIAM A JR","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CCO-Migraine & Common Disease"}}],"security":"Common Shares","published_at":"2022-01-07T21:16:53.000Z","date":"2022-01-06","kind":"tax_withholding","acquired":false,"shares":2230,"price":123.86,"value":276207.8,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"No shares were sold - these shares were withheld by the Issuer to satisfy tax withholding requirements in connection with the vesting of restricted share units."}],"balance_after":11880,"source":{"system":"sec-edgar","filing":"0001562180-22-000351","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1689813/000156218022000351/primarydocument.xml","form_type":"4"}},{"id":2440070,"issuer":{"id":123269,"kind":"organization","name":"Biohaven Pharmaceutical Holding Co Ltd."},"owners":[{"id":1941,"kind":"person","name":"JONES WILLIAM A JR","position":1,"cik":"0001373097","reported_name":"JONES WILLIAM A JR","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CCO-Migraine & Common Disease"}}],"security":"Common Shares","published_at":"2022-01-07T21:16:53.000Z","date":"2022-01-06","kind":"exercise","acquired":true,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"This balance includes 288 shares that were acquired through the Biohaven Employee Share Purchase Plan on May 31, 2021."}],"balance_after":14110,"source":{"system":"sec-edgar","filing":"0001562180-22-000351","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1689813/000156218022000351/primarydocument.xml","form_type":"4"}},{"id":2494257,"issuer":{"id":123269,"kind":"organization","name":"Biohaven Pharmaceutical Holding Co Ltd."},"owners":[{"id":1941,"kind":"person","name":"JONES WILLIAM A JR","position":1,"cik":"0001373097","reported_name":"JONES WILLIAM A JR","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CCO-Migraine & Common Disease"}}],"security":"Restricted Share Unit Award","published_at":"2021-11-26T16:32:48.000Z","date":"2021-11-25","kind":"exercise","acquired":false,"shares":3000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted share unit represents the contingent right to receive one common share of the issuer."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each restricted share unit represents the contingent right to receive one common share of the issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The reporting person was granted 12,000 restricted share units on November 25, 2019, vesting in four equal installments on November 25, 2019, 2020, 2021 and 2022 subject to the reporting person's continued service with the issuer at each vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Not applicable."}],"balance_after":3000,"derivative":{"underlying":"Common Shares","underlying_shares":3000},"source":{"system":"sec-edgar","filing":"0001562180-21-007302","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1689813/000156218021007302/primarydocument.xml","form_type":"4"}},{"id":2494256,"issuer":{"id":123269,"kind":"organization","name":"Biohaven Pharmaceutical Holding Co Ltd."},"owners":[{"id":1941,"kind":"person","name":"JONES WILLIAM A JR","position":1,"cik":"0001373097","reported_name":"JONES WILLIAM A JR","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CCO-Migraine & Common Disease"}}],"security":"Common Shares","published_at":"2021-11-26T16:32:48.000Z","date":"2021-11-25","kind":"tax_withholding","acquired":false,"shares":1305,"price":115.55,"value":150792.75,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"No shares were sold - these shares were withheld by the Issuer to satisfy tax withholding requirements in connection with the vesting of restricted share units."}],"balance_after":8822,"source":{"system":"sec-edgar","filing":"0001562180-21-007302","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1689813/000156218021007302/primarydocument.xml","form_type":"4"}},{"id":2494255,"issuer":{"id":123269,"kind":"organization","name":"Biohaven Pharmaceutical Holding Co Ltd."},"owners":[{"id":1941,"kind":"person","name":"JONES WILLIAM A JR","position":1,"cik":"0001373097","reported_name":"JONES WILLIAM A JR","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CCO-Migraine & Common Disease"}}],"security":"Common Shares","published_at":"2021-11-26T16:32:48.000Z","date":"2021-11-25","kind":"exercise","acquired":true,"shares":3000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":10127,"source":{"system":"sec-edgar","filing":"0001562180-21-007302","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1689813/000156218021007302/primarydocument.xml","form_type":"4"}},{"id":2912291,"issuer":{"id":123269,"kind":"organization","name":"Biohaven Pharmaceutical Holding Co Ltd."},"owners":[{"id":1941,"kind":"person","name":"JONES WILLIAM A JR","position":1,"cik":"0001373097","reported_name":"JONES WILLIAM A JR","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CCO-Migraine & Common Disease"}}],"security":"Restricted Share Unit Award","published_at":"2021-01-08T20:49:07.000Z","date":"2021-01-06","kind":"exercise","acquired":false,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Each restricted share unit represents the contingent right to receive one common share of the Issuer."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Each restricted share unit represents the contingent right to receive one common share of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The reporting person was granted 20,000 restricted share units on January 6, 2021, vesting in four equal installments on January 6, 2021, 2022, 2023 and 2024, subject to the reporting person's continued service with the Issuer at each vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"Not applicable."}],"balance_after":15000,"derivative":{"underlying":"Common Shares","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0001562180-21-000275","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1689813/000156218021000275/primarydocument.xml","form_type":"4"}},{"id":2912290,"issuer":{"id":123269,"kind":"organization","name":"Biohaven Pharmaceutical Holding Co Ltd."},"owners":[{"id":1941,"kind":"person","name":"JONES WILLIAM A JR","position":1,"cik":"0001373097","reported_name":"JONES WILLIAM A JR","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CCO-Migraine & Common Disease"}}],"security":"Restricted Share Unit Award","published_at":"2021-01-08T20:49:07.000Z","date":"2021-01-06","kind":"grant","acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Each restricted share unit represents the contingent right to receive one common share of the Issuer."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Each restricted share unit represents the contingent right to receive one common share of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The reporting person was granted 20,000 restricted share units on January 6, 2021, vesting in four equal installments on January 6, 2021, 2022, 2023 and 2024, subject to the reporting person's continued service with the Issuer at each vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"Not applicable."}],"balance_after":20000,"derivative":{"underlying":"Common Shares","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001562180-21-000275","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1689813/000156218021000275/primarydocument.xml","form_type":"4"}},{"id":2912289,"issuer":{"id":123269,"kind":"organization","name":"Biohaven Pharmaceutical Holding Co Ltd."},"owners":[{"id":1941,"kind":"person","name":"JONES WILLIAM A JR","position":1,"cik":"0001373097","reported_name":"JONES WILLIAM A JR","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CCO-Migraine & Common Disease"}}],"security":"Employee Stock Option (right to buy)","published_at":"2021-01-08T20:49:07.000Z","date":"2021-01-06","kind":"grant","acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares underlying this option vest in four equal installments on January 6, 2021, 2022, 2023 and 2024, subject to the reporting person's continuous service with the Issuer at each vesting date."}],"balance_after":40000,"derivative":{"exercise_price":83.38,"expiration_date":"2031-01-06","underlying":"Common Shares","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001562180-21-000275","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1689813/000156218021000275/primarydocument.xml","form_type":"4"}},{"id":2912288,"issuer":{"id":123269,"kind":"organization","name":"Biohaven Pharmaceutical Holding Co Ltd."},"owners":[{"id":1941,"kind":"person","name":"JONES WILLIAM A JR","position":1,"cik":"0001373097","reported_name":"JONES WILLIAM A JR","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CCO-Migraine & Common Disease"}}],"security":"Common Shares","published_at":"2021-01-08T20:49:07.000Z","date":"2021-01-06","kind":"tax_withholding","acquired":false,"shares":2124,"price":83.38,"value":177099.12,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"No shares were sold - these shares were withheld by the Issuer to satisfy tax withholding requirements in connection with the vesting of restricted share units."}],"balance_after":7127,"source":{"system":"sec-edgar","filing":"0001562180-21-000275","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1689813/000156218021000275/primarydocument.xml","form_type":"4"}},{"id":2912287,"issuer":{"id":123269,"kind":"organization","name":"Biohaven Pharmaceutical Holding Co Ltd."},"owners":[{"id":1941,"kind":"person","name":"JONES WILLIAM A JR","position":1,"cik":"0001373097","reported_name":"JONES WILLIAM A JR","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CCO-Migraine & Common Disease"}}],"security":"Common Shares","published_at":"2021-01-08T20:49:07.000Z","date":"2021-01-06","kind":"exercise","acquired":true,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"This balance includes 741 shares that were acquired through the Biohaven Employee Share Purchase Plan on November 30, 2020."}],"balance_after":9251,"source":{"system":"sec-edgar","filing":"0001562180-21-000275","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1689813/000156218021000275/primarydocument.xml","form_type":"4"}},{"id":2965249,"issuer":{"id":123269,"kind":"organization","name":"Biohaven Pharmaceutical Holding Co Ltd."},"owners":[{"id":1941,"kind":"person","name":"JONES WILLIAM A JR","position":1,"cik":"0001373097","reported_name":"JONES WILLIAM A JR","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CCO-Migraine & Common Disease"}}],"security":"Restricted Share Unit Award","published_at":"2020-11-27T21:48:09.000Z","date":"2020-11-25","kind":"exercise","acquired":false,"shares":3000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted share unit represents the contingent right to receive one common share of Biohaven Pharmaceutical Holding Co Ltd."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each restricted share unit represents the contingent right to receive one common share of Biohaven Pharmaceutical Holding Co Ltd."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The reporting person was granted 12,000 restricted share units on November 25, 2019, vesting in four equal installments on November 25, 2019, 2020, 2021 and 2022 subject to the reporting person's continued service with the issuer at each vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Not applicable."}],"balance_after":6000,"derivative":{"underlying":"Common Shares","underlying_shares":3000},"source":{"system":"sec-edgar","filing":"0001562180-20-006940","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1689813/000156218020006940/primarydocument.xml","form_type":"4"}},{"id":2965248,"issuer":{"id":123269,"kind":"organization","name":"Biohaven Pharmaceutical Holding Co Ltd."},"owners":[{"id":1941,"kind":"person","name":"JONES WILLIAM A JR","position":1,"cik":"0001373097","reported_name":"JONES WILLIAM A JR","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CCO-Migraine & Common Disease"}}],"security":"Common Shares","published_at":"2020-11-27T21:48:09.000Z","date":"2020-11-25","kind":"tax_withholding","acquired":false,"shares":1245,"price":90.14,"value":112224.3,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"No shares were sold - these shares were withheld by the Issuer to satisfy tax withholding requirements in connection with the vesting of restricted share units."}],"balance_after":3510,"source":{"system":"sec-edgar","filing":"0001562180-20-006940","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1689813/000156218020006940/primarydocument.xml","form_type":"4"}},{"id":2965247,"issuer":{"id":123269,"kind":"organization","name":"Biohaven Pharmaceutical Holding Co Ltd."},"owners":[{"id":1941,"kind":"person","name":"JONES WILLIAM A JR","position":1,"cik":"0001373097","reported_name":"JONES WILLIAM A JR","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CCO-Migraine & Common Disease"}}],"security":"Common Shares","published_at":"2020-11-27T21:48:09.000Z","date":"2020-11-25","kind":"exercise","acquired":true,"shares":3000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":4755,"source":{"system":"sec-edgar","filing":"0001562180-20-006940","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1689813/000156218020006940/primarydocument.xml","form_type":"4"}},{"id":2992881,"issuer":{"id":123269,"kind":"organization","name":"Biohaven Pharmaceutical Holding Co Ltd."},"owners":[{"id":1941,"kind":"person","name":"JONES WILLIAM A JR","position":1,"cik":"0001373097","reported_name":"JONES WILLIAM A JR","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CCO-Migraine & Common Disease"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2020-11-04T20:31:03.000Z","date":"2020-11-02","kind":"exercise","acquired":false,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These exercises and sales were made pursuant to a 10b5-1 trading plan adopted by the Reporting Person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The shares underlying this option vest in three equal installments on April 1, 2019, April 1, 2020 and April 1, 2021, subject to the Reporting Person's continuous service with the Issuer at each vesting date."}],"balance_after":50000,"derivative":{"exercise_price":50.72,"expiration_date":"2029-03-31","underlying":"Common Shares","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001562180-20-006560","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1689813/000156218020006560/primarydocument.xml","form_type":"4"}},{"id":2992880,"issuer":{"id":123269,"kind":"organization","name":"Biohaven Pharmaceutical Holding Co Ltd."},"owners":[{"id":1941,"kind":"person","name":"JONES WILLIAM A JR","position":1,"cik":"0001373097","reported_name":"JONES WILLIAM A JR","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CCO-Migraine & Common Disease"}}],"security":"Common Shares","published_at":"2020-11-04T20:31:03.000Z","date":"2020-11-02","kind":"sale","acquired":false,"shares":1300,"price":77.6962,"value":101005.06,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These exercises and sales were made pursuant to a 10b5-1 trading plan adopted by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $77.55 - $77.82, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4."}],"balance_after":1755,"source":{"system":"sec-edgar","filing":"0001562180-20-006560","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1689813/000156218020006560/primarydocument.xml","form_type":"4"}},{"id":2992879,"issuer":{"id":123269,"kind":"organization","name":"Biohaven Pharmaceutical Holding Co Ltd."},"owners":[{"id":1941,"kind":"person","name":"JONES WILLIAM A JR","position":1,"cik":"0001373097","reported_name":"JONES WILLIAM A JR","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CCO-Migraine & Common Disease"}}],"security":"Common Shares","published_at":"2020-11-04T20:31:03.000Z","date":"2020-11-02","kind":"sale","acquired":false,"shares":4010,"price":77.0073,"value":308799.273,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These exercises and sales were made pursuant to a 10b5-1 trading plan adopted by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $76.54 - $77.43, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4."}],"balance_after":3055,"source":{"system":"sec-edgar","filing":"0001562180-20-006560","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1689813/000156218020006560/primarydocument.xml","form_type":"4"}},{"id":2992878,"issuer":{"id":123269,"kind":"organization","name":"Biohaven Pharmaceutical Holding Co Ltd."},"owners":[{"id":1941,"kind":"person","name":"JONES WILLIAM A JR","position":1,"cik":"0001373097","reported_name":"JONES WILLIAM A JR","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CCO-Migraine & Common Disease"}}],"security":"Common Shares","published_at":"2020-11-04T20:31:03.000Z","date":"2020-11-02","kind":"sale","acquired":false,"shares":24690,"price":76.0175,"value":1876872.075,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These exercises and sales were made pursuant to a 10b5-1 trading plan adopted by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $75.53 - $76.46, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4."}],"balance_after":7065,"source":{"system":"sec-edgar","filing":"0001562180-20-006560","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1689813/000156218020006560/primarydocument.xml","form_type":"4"}},{"id":2992877,"issuer":{"id":123269,"kind":"organization","name":"Biohaven Pharmaceutical Holding Co Ltd."},"owners":[{"id":1941,"kind":"person","name":"JONES WILLIAM A JR","position":1,"cik":"0001373097","reported_name":"JONES WILLIAM A JR","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CCO-Migraine & Common Disease"}}],"security":"Common Shares","published_at":"2020-11-04T20:31:03.000Z","date":"2020-11-02","kind":"exercise","acquired":true,"shares":30000,"price":50.72,"value":1521600.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These exercises and sales were made pursuant to a 10b5-1 trading plan adopted by the Reporting Person."}],"balance_after":31755,"source":{"system":"sec-edgar","filing":"0001562180-20-006560","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1689813/000156218020006560/primarydocument.xml","form_type":"4"}},{"id":3333959,"issuer":{"id":123269,"kind":"organization","name":"Biohaven Pharmaceutical Holding Co Ltd."},"owners":[{"id":1941,"kind":"person","name":"JONES WILLIAM A JR","position":1,"cik":"0001373097","reported_name":"JONES WILLIAM A JR","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CCO-Migraine & Common Disease"}}],"security":"Restricted Share Unit Award","published_at":"2019-12-20T21:40:56.000Z","date":"2019-12-18","kind":"exercise","acquired":false,"shares":3000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted share unit represents the contingent right to receive one common share of Biohaven Pharmaceutical Holding Co Ltd."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each restricted share unit represents the contingent right to receive one common share of Biohaven Pharmaceutical Holding Co Ltd."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The reporting person was granted 12,000 restricted share units on November 25, 2019, vesting in four equal installments on November 25, 2019, 2020, 2021 and 2022 subject to the reporting person's continued service with the issuer at each vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Not applicable."}],"balance_after":9000,"derivative":{"underlying":"Common Shares","underlying_shares":3000},"source":{"system":"sec-edgar","filing":"0001689813-19-000132","document":"wf-form4_157689603813307.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1689813/000168981319000132/wf-form4_157689603813307.xml","form_type":"4"}},{"id":3333958,"issuer":{"id":123269,"kind":"organization","name":"Biohaven Pharmaceutical Holding Co Ltd."},"owners":[{"id":1941,"kind":"person","name":"JONES WILLIAM A JR","position":1,"cik":"0001373097","reported_name":"JONES WILLIAM A JR","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CCO-Migraine & Common Disease"}}],"security":"Common Shares","published_at":"2019-12-20T21:40:56.000Z","date":"2019-12-18","kind":"tax_withholding","acquired":false,"shares":1245,"price":52.13,"value":64901.85,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"No shares were sold - these shares were withheld by the Issuer to satisfy tax withholding requirements in connection with the vesting of restricted share units."}],"balance_after":1755,"source":{"system":"sec-edgar","filing":"0001689813-19-000132","document":"wf-form4_157689603813307.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1689813/000168981319000132/wf-form4_157689603813307.xml","form_type":"4"}},{"id":3333957,"issuer":{"id":123269,"kind":"organization","name":"Biohaven Pharmaceutical Holding Co Ltd."},"owners":[{"id":1941,"kind":"person","name":"JONES WILLIAM A JR","position":1,"cik":"0001373097","reported_name":"JONES WILLIAM A JR","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CCO-Migraine & Common Disease"}}],"security":"Common Shares","published_at":"2019-12-20T21:40:56.000Z","date":"2019-12-18","kind":"exercise","acquired":true,"shares":3000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":3000,"source":{"system":"sec-edgar","filing":"0001689813-19-000132","document":"wf-form4_157689603813307.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1689813/000168981319000132/wf-form4_157689603813307.xml","form_type":"4"}},{"id":3357652,"issuer":{"id":123269,"kind":"organization","name":"Biohaven Pharmaceutical Holding Co Ltd."},"owners":[{"id":1941,"kind":"person","name":"JONES WILLIAM A JR","position":1,"cik":"0001373097","reported_name":"JONES WILLIAM A JR","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CCO-Migraine & Common Disease"}}],"security":"Restricted Share Unit Award","published_at":"2019-11-27T21:31:52.000Z","date":"2019-11-25","kind":"grant","acquired":true,"shares":12000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted share unit represents the contingent right to receive one common share of Biohaven Pharmaceutical Holding Co Ltd."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each restricted share unit represents the contingent right to receive one common share of Biohaven Pharmaceutical Holding Co Ltd."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The reporting person was granted 12,000 restricted share units on November 25, 2019, vesting in four equal installments on November 25, 2019, 2020, 2021 and 2022 subject to the reporting person's continued service with the issuer at each vesting date."}],"balance_after":12000,"derivative":{"expiration_date":"2022-11-24","underlying":"Common Shares","underlying_shares":12000},"source":{"system":"sec-edgar","filing":"0001689813-19-000113","document":"wf-form4_157490829443108.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1689813/000168981319000113/wf-form4_157490829443108.xml","form_type":"4"}},{"id":3357651,"issuer":{"id":123269,"kind":"organization","name":"Biohaven Pharmaceutical Holding Co Ltd."},"owners":[{"id":1941,"kind":"person","name":"JONES WILLIAM A JR","position":1,"cik":"0001373097","reported_name":"JONES WILLIAM A JR","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CCO-Migraine & Common Disease"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2019-11-27T21:31:52.000Z","date":"2019-11-25","kind":"grant","acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this option vest in four equal installments on November 25, 2019, 2020, 2021 and 2022, subject to the optionholder's continuous service with the issuer at each vesting date."}],"balance_after":30000,"derivative":{"exercise_price":57.4,"expiration_date":"2029-11-24","underlying":"Common Shares","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001689813-19-000113","document":"wf-form4_157490829443108.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1689813/000168981319000113/wf-form4_157490829443108.xml","form_type":"4"}},{"id":3565105,"issuer":{"id":123269,"kind":"organization","name":"Biohaven Pharmaceutical Holding Co Ltd."},"owners":[{"id":1941,"kind":"person","name":"JONES WILLIAM A JR","position":1,"cik":"0001373097","reported_name":"JONES WILLIAM A JR","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CCO-Migraine & Common Disease"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2019-04-03T18:17:13.000Z","date":"2019-04-01","kind":"grant","acquired":true,"shares":80000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this option vest in three equal installments on April 1, 2019, April 1, 2020 and April 1, 2021, subject to the Reporting Person's continuous service with the Issuer at each vesting date."}],"balance_after":80000,"derivative":{"exercise_price":50.72,"expiration_date":"2029-03-31","underlying":"Common Shares","underlying_shares":80000},"source":{"system":"sec-edgar","filing":"0001209191-19-023435","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1689813/000120919119023435/doc4.xml","form_type":"4"}}]}